首页 > 最新文献

European Journal of Health Economics最新文献

英文 中文
Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review. 检测生物流体生物标志物诊断阿尔茨海默病的成本效益:系统综述
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-12 DOI: 10.1007/s10198-025-01877-1
Hanzi Jiang, Sergio Escamilla, Molly Beestrum, Federico Salas-Lucia

Background: Alzheimer's disease (AD) affects tens of millions of individuals and their families in the world. As AD progresses, the effectiveness of treatment declines, making a timely diagnosis crucial. One promising approach for timely diagnosis is testing biofluid biomarkers in patients' blood and cerebrospinal fluid (CSF). However, a comprehensive evaluation of whether these tests are cost-effective is missing. Here, we conducted a systematic review to assess the cost-effectiveness of testing biofluid biomarkers to diagnose AD.

Method: We searched PubMed, Embase, Cochrane Library, and Web of Science for studies published until October 2024. Studies were included if published in English, conducted an economic evaluation of CSF or blood biomarker testing to diagnose AD, and provided economic outcomes. We assessed the quality of studies using the CHEERS 2022 criteria.

Results: Nine studies were included: six evaluated CSF biomarker tests and three on blood biomarker tests. All studies used model-based simulations (decision trees or Markov models) rather than trial-based evaluations. CSF biomarker tests were mostly cost-effective compared to neurocognitive assessments or neuroimaging, while blood biomarker tests showed mixed results. Key cost-effectiveness contributors included AD prevalence, diagnostic accuracy, and treatment effectiveness. Studies met ~ 80% of the CHEERS criteria, with missing information on patient engagement.

Conclusion: Our review supports that biofluid biomarker testing could be cost-effective to diagnose AD. Given the lack of trial-based economic evaluations, model-based studies are a valuable starting point. Future evaluations should incorporate patient-centered outcomes and consider the emotional value and other socio-economic factors that affect patients and families suffering from AD.

背景:阿尔茨海默病(AD)影响着世界上数以千万计的个人及其家庭。随着阿尔茨海默病的进展,治疗的有效性下降,及时诊断至关重要。一种有希望的及时诊断方法是检测患者血液和脑脊液(CSF)中的生物流体生物标志物。然而,缺乏对这些检测是否具有成本效益的全面评估。在这里,我们进行了一项系统综述,以评估检测生物流体生物标志物诊断AD的成本效益。方法:检索PubMed、Embase、Cochrane Library和Web of Science,检索截止到2024年10月发表的研究。研究纳入了以英语发表的研究,对CSF或血液生物标志物检测诊断AD进行了经济评估,并提供了经济结果。我们使用CHEERS 2022标准评估研究的质量。结果:纳入9项研究:6项评估CSF生物标志物试验,3项评估血液生物标志物试验。所有研究都使用基于模型的模拟(决策树或马尔可夫模型),而不是基于试验的评估。与神经认知评估或神经成像相比,脑脊液生物标志物测试大多具有成本效益,而血液生物标志物测试显示的结果好坏参半。主要的成本效益因素包括AD患病率、诊断准确性和治疗效果。研究满足约80%的CHEERS标准,缺少患者参与的信息。结论:本综述支持生物流体生物标志物检测在AD诊断中具有成本效益。鉴于缺乏基于试验的经济评估,基于模型的研究是一个有价值的起点。未来的评估应纳入以患者为中心的结果,并考虑影响AD患者和家庭的情感价值和其他社会经济因素。
{"title":"Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.","authors":"Hanzi Jiang, Sergio Escamilla, Molly Beestrum, Federico Salas-Lucia","doi":"10.1007/s10198-025-01877-1","DOIUrl":"https://doi.org/10.1007/s10198-025-01877-1","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) affects tens of millions of individuals and their families in the world. As AD progresses, the effectiveness of treatment declines, making a timely diagnosis crucial. One promising approach for timely diagnosis is testing biofluid biomarkers in patients' blood and cerebrospinal fluid (CSF). However, a comprehensive evaluation of whether these tests are cost-effective is missing. Here, we conducted a systematic review to assess the cost-effectiveness of testing biofluid biomarkers to diagnose AD.</p><p><strong>Method: </strong>We searched PubMed, Embase, Cochrane Library, and Web of Science for studies published until October 2024. Studies were included if published in English, conducted an economic evaluation of CSF or blood biomarker testing to diagnose AD, and provided economic outcomes. We assessed the quality of studies using the CHEERS 2022 criteria.</p><p><strong>Results: </strong>Nine studies were included: six evaluated CSF biomarker tests and three on blood biomarker tests. All studies used model-based simulations (decision trees or Markov models) rather than trial-based evaluations. CSF biomarker tests were mostly cost-effective compared to neurocognitive assessments or neuroimaging, while blood biomarker tests showed mixed results. Key cost-effectiveness contributors included AD prevalence, diagnostic accuracy, and treatment effectiveness. Studies met ~ 80% of the CHEERS criteria, with missing information on patient engagement.</p><p><strong>Conclusion: </strong>Our review supports that biofluid biomarker testing could be cost-effective to diagnose AD. Given the lack of trial-based economic evaluations, model-based studies are a valuable starting point. Future evaluations should incorporate patient-centered outcomes and consider the emotional value and other socio-economic factors that affect patients and families suffering from AD.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-utility of focused ultrasound compared to radiotherapy for Dutch patients with uncomplicated non-spinal bone metastases. 聚焦超声对荷兰无并发症非脊柱骨转移患者放疗的成本-效用比较。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-05 DOI: 10.1007/s10198-025-01861-9
Julia Simões Corrêa Galendi, Ingrid Nijholt, Renée Hovenier, Jorik Slotman, Erik Phernambucq, Stephanie Stock, Clemens Bos, Manon Braat, Helena Verkooijen, Martijn Boomsma, Dirk Müller

Introduction: Non-randomized clinical trial has shown that Magnetic Resonance guided High-intensity focused ultrasound (MR-HIFU) leads to faster pain relief compared to the current standard of care External Beam Radiotherapy (EBRT).

Objective: To evaluate the cost-utility of 'early MR-HIFU' (with optional EBRT afterwards) or 'delayed MR-HIFU' (i.e., MR-HIFU after failed EBRT) versus EBRT (with optional re-irradiation with EBRT) from the societal perspective in the Netherlands METHODS: A lifelong patient-level simulation model was developed. After a treatment with either MR-HIFU or EBRT, a patient could have: (i) complete pain relief, (ii) partial pain relief, (iii) persistent pain and (iv) death. We also accounted for the event of a pathological fracture. Model outputs were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). The net monetary benefit was calculated considering the willingness-to-pay threshold of €80,000 per QALY gained, adjusted by the Dutch disease severity index. Deterministic and probabilistic sensitivity analyses were conducted.

Results: The strategy 'delayed MR-HIFU' costs €706 more than EBRT, whilst 'early MR-HIFU' costs €1,875 more than EBRT.'Early MR-HIFU' adds 0,15 more QALYs than EBRT, resulting in an ICER of €12.755 per QALY and an incremental net monetary benefit of €8,631. At a threshold of 80,000€ per QALY there is a 77% probability that 'early MR-HIFU' is the most cost-effective option.

Conclusion: Although there are still uncertainties relating to implementation of MR-HIFU in patient care, our modelling study shows that offering MR-HIFU as an early treatment would be the most cost-effective option in the Netherlands.

简介:非随机临床试验表明,与目前的标准护理外束放疗(EBRT)相比,磁共振引导的高强度聚焦超声(MR-HIFU)可以更快地缓解疼痛。目的:从荷兰的社会角度评估“早期MR-HIFU”(之后可选择EBRT)或“延迟MR-HIFU”(即EBRT失败后的MR-HIFU)与EBRT(可选择EBRT再照射)的成本-效用。方法:开发了终身患者水平的模拟模型。在MR-HIFU或EBRT治疗后,患者可能有:(i)完全疼痛缓解,(ii)部分疼痛缓解,(iii)持续疼痛和(iv)死亡。我们也考虑到了病理性骨折的情况。模型输出为成本、质量调整寿命年(QALYs)和增量成本-效果比(ICER)。根据荷兰疾病严重程度指数进行调整,考虑到每个QALY获得8万欧元的支付意愿门槛,计算了净货币收益。进行了确定性和概率敏感性分析。结果:“延迟MR-HIFU”策略比EBRT多花费706欧元,而“早期MR-HIFU”策略比EBRT多花费1875欧元。“早期MR-HIFU”比EBRT增加了0.15个QALY,导致每个QALY的ICER为12.755欧元,增量净货币收益为8,631欧元。在每个QALY 80,000欧元的门槛下,“早期MR-HIFU”是最具成本效益的选择的可能性为77%。结论:尽管在患者护理中实施MR-HIFU仍存在不确定性,但我们的模型研究表明,在荷兰,提供MR-HIFU作为早期治疗将是最具成本效益的选择。
{"title":"Cost-utility of focused ultrasound compared to radiotherapy for Dutch patients with uncomplicated non-spinal bone metastases.","authors":"Julia Simões Corrêa Galendi, Ingrid Nijholt, Renée Hovenier, Jorik Slotman, Erik Phernambucq, Stephanie Stock, Clemens Bos, Manon Braat, Helena Verkooijen, Martijn Boomsma, Dirk Müller","doi":"10.1007/s10198-025-01861-9","DOIUrl":"https://doi.org/10.1007/s10198-025-01861-9","url":null,"abstract":"<p><strong>Introduction: </strong>Non-randomized clinical trial has shown that Magnetic Resonance guided High-intensity focused ultrasound (MR-HIFU) leads to faster pain relief compared to the current standard of care External Beam Radiotherapy (EBRT).</p><p><strong>Objective: </strong>To evaluate the cost-utility of 'early MR-HIFU' (with optional EBRT afterwards) or 'delayed MR-HIFU' (i.e., MR-HIFU after failed EBRT) versus EBRT (with optional re-irradiation with EBRT) from the societal perspective in the Netherlands METHODS: A lifelong patient-level simulation model was developed. After a treatment with either MR-HIFU or EBRT, a patient could have: (i) complete pain relief, (ii) partial pain relief, (iii) persistent pain and (iv) death. We also accounted for the event of a pathological fracture. Model outputs were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). The net monetary benefit was calculated considering the willingness-to-pay threshold of €80,000 per QALY gained, adjusted by the Dutch disease severity index. Deterministic and probabilistic sensitivity analyses were conducted.</p><p><strong>Results: </strong>The strategy 'delayed MR-HIFU' costs €706 more than EBRT, whilst 'early MR-HIFU' costs €1,875 more than EBRT.'Early MR-HIFU' adds 0,15 more QALYs than EBRT, resulting in an ICER of €12.755 per QALY and an incremental net monetary benefit of €8,631. At a threshold of 80,000€ per QALY there is a 77% probability that 'early MR-HIFU' is the most cost-effective option.</p><p><strong>Conclusion: </strong>Although there are still uncertainties relating to implementation of MR-HIFU in patient care, our modelling study shows that offering MR-HIFU as an early treatment would be the most cost-effective option in the Netherlands.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L. SF-6Dv2和EQ-5D-5L心理测量性能的跨国比较。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-05 DOI: 10.1007/s10198-025-01867-3
Hosein Ameri, Brendan Mulhern, Richard Norman, Takeru Shiroiwa, Rajabali Daroudi, Thomas G Poder

Objective: To evaluate the comparative performance of SF-6Dv2 and EQ-5D-5L in the general population of Quebec (Canada), Tehran (Iran), and Japan.

Methods: Data on SF-6Dv2 and EQ-5D-5L were collected in the three countries. Descriptive differences in utility values between SF-6Dv2 and EQ-5D-5L were assessed using t-tests, as well as ceiling effects were evaluated based on the percentage of "no problem" levels reported. The known-group validity of both measures was assessed by comparing utility scores across health and demographic subgroups using t-tests or ANOVA and by calculating effect sizes across known groups. The area under the receiver operating characteristic curve (AUROC) analysis and F-statistic ratios were used to further validate the findings from the known-group validity analyses. Convergent validity for both instruments was assessed using Spearman's rank correlation coefficient. The agreement between instruments was evaluated using intraclass correlation coefficients (ICC) and Bland-Altman plots.

Results: A total of 2,378 respondents for Quebec, 3,061 for Tehran, and 3,933 for Japan were included. Differences in utility values between SF-6Dv2 and EQ-5D-5L were statistically significant, with SF-6Dv2 generally yielding lower utility scores. Both instruments demonstrated strong known-group validity, effectively distinguishing between diseased and healthy groups as well as various demographic characteristics. However, EQ-5D-5L outperformed SF-6Dv2 for most demographic characteristics based on AUROC analysis and F-statistic ratios. In contrast, their performance in distinguishing between healthy and diseased groups did not favor a particular instrument. Convergent validity analyses indicated strong associations between SF-6Dv2 and EQ-5D-5L utility values in Quebec (0.760) and Tehran (0.737). The agreement between SF-6Dv2 and EQ-5D-5L utility values was moderate in Quebec (0.69) and strong in Tehran (0.837). Bland-Altman plots indicated that differences between the two instruments tended to increase as the average score decreased.

Conclusion: Both EQ-5D-5L and SF-6Dv2 demonstrated favorable psychometric performance in terms of known-group validity and convergent validity. These findings suggest that both instruments are valid tools for health utility measurement for use in general population.

目的:评价SF-6Dv2和EQ-5D-5L在魁北克(加拿大)、德黑兰(伊朗)和日本的普通人群中的比较表现。方法:收集三个国家的SF-6Dv2和EQ-5D-5L数据。使用t检验评估SF-6Dv2和EQ-5D-5L之间效用值的描述性差异,并根据报告的“无问题”水平的百分比评估上限效应。通过使用t检验或方差分析比较健康和人口统计学亚组的效用得分,并通过计算已知组间的效应量,来评估这两种措施的已知组效度。采用受试者工作特征曲线下面积(AUROC)分析和f统计比进一步验证已知组效度分析的结果。采用Spearman等级相关系数评估两种工具的收敛效度。使用类内相关系数(ICC)和Bland-Altman图评估仪器之间的一致性。结果:魁北克共有2378名受访者,德黑兰有3061名,日本有3933名。SF-6Dv2与EQ-5D-5L的效用值差异有统计学意义,SF-6Dv2的效用得分普遍较低。这两种工具都显示出强大的已知组效度,有效地区分了患病和健康群体以及各种人口统计学特征。然而,基于AUROC分析和f统计比,EQ-5D-5L在大多数人口统计学特征上优于SF-6Dv2。相比之下,他们在区分健康和患病群体方面的表现并不青睐特定的仪器。收敛效度分析表明,魁北克(0.760)和德黑兰(0.737)的SF-6Dv2和EQ-5D-5L效用值之间存在很强的相关性。SF-6Dv2和EQ-5D-5L效用值在魁北克的一致性中等(0.69),在德黑兰的一致性较强(0.837)。Bland-Altman图表明,随着平均分数的下降,两种工具之间的差异趋于增加。结论:EQ-5D-5L和SF-6Dv2在已知组效度和收敛效度方面均表现出良好的心理测量性能。这些发现表明,这两种仪器都是测量健康效用的有效工具,可在一般人群中使用。
{"title":"A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L.","authors":"Hosein Ameri, Brendan Mulhern, Richard Norman, Takeru Shiroiwa, Rajabali Daroudi, Thomas G Poder","doi":"10.1007/s10198-025-01867-3","DOIUrl":"https://doi.org/10.1007/s10198-025-01867-3","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the comparative performance of SF-6Dv2 and EQ-5D-5L in the general population of Quebec (Canada), Tehran (Iran), and Japan.</p><p><strong>Methods: </strong>Data on SF-6Dv2 and EQ-5D-5L were collected in the three countries. Descriptive differences in utility values between SF-6Dv2 and EQ-5D-5L were assessed using t-tests, as well as ceiling effects were evaluated based on the percentage of \"no problem\" levels reported. The known-group validity of both measures was assessed by comparing utility scores across health and demographic subgroups using t-tests or ANOVA and by calculating effect sizes across known groups. The area under the receiver operating characteristic curve (AUROC) analysis and F-statistic ratios were used to further validate the findings from the known-group validity analyses. Convergent validity for both instruments was assessed using Spearman's rank correlation coefficient. The agreement between instruments was evaluated using intraclass correlation coefficients (ICC) and Bland-Altman plots.</p><p><strong>Results: </strong>A total of 2,378 respondents for Quebec, 3,061 for Tehran, and 3,933 for Japan were included. Differences in utility values between SF-6Dv2 and EQ-5D-5L were statistically significant, with SF-6Dv2 generally yielding lower utility scores. Both instruments demonstrated strong known-group validity, effectively distinguishing between diseased and healthy groups as well as various demographic characteristics. However, EQ-5D-5L outperformed SF-6Dv2 for most demographic characteristics based on AUROC analysis and F-statistic ratios. In contrast, their performance in distinguishing between healthy and diseased groups did not favor a particular instrument. Convergent validity analyses indicated strong associations between SF-6Dv2 and EQ-5D-5L utility values in Quebec (0.760) and Tehran (0.737). The agreement between SF-6Dv2 and EQ-5D-5L utility values was moderate in Quebec (0.69) and strong in Tehran (0.837). Bland-Altman plots indicated that differences between the two instruments tended to increase as the average score decreased.</p><p><strong>Conclusion: </strong>Both EQ-5D-5L and SF-6Dv2 demonstrated favorable psychometric performance in terms of known-group validity and convergent validity. These findings suggest that both instruments are valid tools for health utility measurement for use in general population.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The disability and care squeeze: the effects of children's disability and special healthcare needs on parents' employment in Australia. 残疾和护理压力:儿童残疾和特殊保健需求对澳大利亚父母就业的影响。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-05 DOI: 10.1007/s10198-025-01878-0
Benojir Ahammed, Khorshed Alam, Zahirul Hoque, Syed Afroz Keramat

Background: Children with disabilities and special healthcare needs can considerably affect parental employment and family financial stability. This study aims to investigate the effects of children's disabilities, special healthcare needs, and their coexistence on parental employment in Australia.

Methods: This study utilised data from the nationally representative Baby (B) and Kindergarten (K) cohorts, spanning Waves 1 to 8 of the Longitudinal Study of Australian Children (LSAC). Fixed-effects logistic regression was employed to examine the relationship between children's disability, special healthcare needs, and parental (for both mothers and fathers) employment status.

Results: The findings show that within the same family, children's disability (adjusted odds ratio [aOR] = 0.81, 95% confidence interval [CI]: 0.70-0.94, p = 0.006) and having a child with special healthcare needs (aOR = 0.87, 95% CI: 0.76-0.99, p = 0.038) reduces the likelihood of a mother being employed. Furthermore, the results indicate that the interaction between disability and special healthcare needs (aOR = 0.69, 95% CI: 0.56-0.87, p = 0.001) significantly reduces the likelihood of mothers' participation in employment. Similarly, the findings show that within the same family, having a child with a disability (aOR = 0.60, 95% CI: 0.45-0.78, p < 0.001) results in a 40% decrease in the odds of paternal employment.

Conclusion: Children with disabilities and special healthcare needs significantly reduce maternal employment participation within the same family, while only disabilities are associated with reduced employment for fathers. These findings offer vital evidence for policymakers to improve support systems for families with children who have disabilities and special healthcare needs. Such support may include access to essential services and resources, leading to improved parental employment outcomes and enhanced overall family well-being.

背景:残疾儿童和有特殊保健需要的儿童会严重影响父母的就业和家庭的经济稳定。本研究旨在调查儿童残疾、特殊保健需求及其共存对澳大利亚父母就业的影响。方法:本研究利用了来自全国具有代表性的婴儿(B)和幼儿园(K)队列的数据,跨越澳大利亚儿童纵向研究(LSAC)的第1至8波。采用固定效应logistic回归检验儿童残疾、特殊医疗保健需求和父母(母亲和父亲)就业状况之间的关系。结果:研究结果显示,在同一家庭中,儿童残疾(调整优势比[aOR] = 0.81, 95%可信区间[CI]: 0.70-0.94, p = 0.006)和有特殊保健需求的儿童(aOR = 0.87, 95% CI: 0.76-0.99, p = 0.038)降低了母亲就业的可能性。此外,结果表明,残疾与特殊医疗保健需求之间的相互作用(aOR = 0.69, 95% CI: 0.56-0.87, p = 0.001)显著降低了母亲参与就业的可能性。同样,研究结果表明,在同一个家庭中,有一个残疾儿童(aOR = 0.60, 95% CI: 0.45-0.78, p),结论:残疾儿童和特殊保健需求显著降低了同一家庭中母亲的就业参与,而只有残疾儿童与父亲的就业减少有关。这些发现为决策者改善有残疾儿童和特殊医疗需求家庭的支持系统提供了重要证据。这种支持可能包括获得基本服务和资源,从而改善父母的就业结果,增强整体家庭福祉。
{"title":"The disability and care squeeze: the effects of children's disability and special healthcare needs on parents' employment in Australia.","authors":"Benojir Ahammed, Khorshed Alam, Zahirul Hoque, Syed Afroz Keramat","doi":"10.1007/s10198-025-01878-0","DOIUrl":"https://doi.org/10.1007/s10198-025-01878-0","url":null,"abstract":"<p><strong>Background: </strong>Children with disabilities and special healthcare needs can considerably affect parental employment and family financial stability. This study aims to investigate the effects of children's disabilities, special healthcare needs, and their coexistence on parental employment in Australia.</p><p><strong>Methods: </strong>This study utilised data from the nationally representative Baby (B) and Kindergarten (K) cohorts, spanning Waves 1 to 8 of the Longitudinal Study of Australian Children (LSAC). Fixed-effects logistic regression was employed to examine the relationship between children's disability, special healthcare needs, and parental (for both mothers and fathers) employment status.</p><p><strong>Results: </strong>The findings show that within the same family, children's disability (adjusted odds ratio [aOR] = 0.81, 95% confidence interval [CI]: 0.70-0.94, p = 0.006) and having a child with special healthcare needs (aOR = 0.87, 95% CI: 0.76-0.99, p = 0.038) reduces the likelihood of a mother being employed. Furthermore, the results indicate that the interaction between disability and special healthcare needs (aOR = 0.69, 95% CI: 0.56-0.87, p = 0.001) significantly reduces the likelihood of mothers' participation in employment. Similarly, the findings show that within the same family, having a child with a disability (aOR = 0.60, 95% CI: 0.45-0.78, p < 0.001) results in a 40% decrease in the odds of paternal employment.</p><p><strong>Conclusion: </strong>Children with disabilities and special healthcare needs significantly reduce maternal employment participation within the same family, while only disabilities are associated with reduced employment for fathers. These findings offer vital evidence for policymakers to improve support systems for families with children who have disabilities and special healthcare needs. Such support may include access to essential services and resources, leading to improved parental employment outcomes and enhanced overall family well-being.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors. 颅咽管瘤和其他罕见鞍/鞍上肿瘤患者下丘脑肥胖的经济学研究
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-05-09 DOI: 10.1007/s10198-025-01786-3
Julian Witte, Nicolas Touchot, Bastian Surmann, Kylie Braegelmann, Mathias Flume, Julia Beckhaus, Carsten Friedrich, Hermann L Müller

Background: Rapid and abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment-related damage to the hypothalamus, is called acquired hypothalamic obesity (aHO), and is often linked to craniopharyngioma and/or sellar/suprasellar tumors. Here, we examine the healthcare resource use (HCRU) and costs of aHO following treatment of these tumors.

Methods: We used a retrospective matched cohort design with German statutory health insurance data on 5.42 million people from 2010 to 2021. We applied a novel three-step approach using diagnostic and prescription data to identify patients with treatment- or tumor-related (TTR)-aHO. We measured HCRU and costs across hospitalizations, outpatient visits, visits per specialist group, and outpatient prescription medications.

Results: Compared to non-HO obesity, TTR-aHO is associated with increased hospitalizations, increased outpatient physician visits, and increased prescription use in the two years after incident tumor surgery/radiotherapy. Excess costs of TTR-aHO are €19,900 per patient in the first year and €10,700 in the second, driven by inpatient costs. Cost-intensive hormone replacement therapies like somatropin lead to a sharp increase in prescription costs in the second year.

Conclusions: This study provides the first real-world analysis of TTR-aHO economics, emphasizing the importance of HCRU and costs for decision-making. Previously, economic evaluations have been missing due to the lack of a standard method to identify patients with aHO in retrospective studies. Using a new identification approach, the study reveals that TTR-aHO poses a significant burden in extensive treatment requirements for patients and high related costs for the healthcare system.

背景:由于身体、肿瘤和/或治疗相关的下丘脑损伤,导致体重迅速和异常增加,导致严重的持续性肥胖,称为获得性下丘脑肥胖(aHO),通常与颅咽管瘤和/或鞍上/鞍上肿瘤有关。在这里,我们检查了这些肿瘤治疗后的卫生保健资源使用(HCRU)和卫生组织费用。方法:我们采用回顾性匹配队列设计,纳入2010年至2021年542万人的德国法定医疗保险数据。我们采用了一种新的三步方法,使用诊断和处方数据来识别治疗或肿瘤相关(TTR)- aho患者。我们测量了HCRU和住院、门诊就诊、每个专科就诊和门诊处方药的成本。结果:与非ho肥胖相比,ttr - ho与肿瘤手术/放疗后两年内住院次数增加、门诊医生就诊次数增加和处方使用增加有关。由于住院费用的原因,ttr - who第一年的超额成本为每位患者19,900欧元,第二年为10,700欧元。成本高昂的激素替代疗法,如生长激素,会在第二年导致处方费用急剧上升。结论:本研究首次对ttr - who经济学进行了现实世界的分析,强调了HCRU和决策成本的重要性。以前,由于在回顾性研究中缺乏确定who患者的标准方法,因此缺少经济评估。使用一种新的识别方法,该研究表明,ttr - who对患者的广泛治疗需求和卫生保健系统的高相关费用构成了重大负担。
{"title":"Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors.","authors":"Julian Witte, Nicolas Touchot, Bastian Surmann, Kylie Braegelmann, Mathias Flume, Julia Beckhaus, Carsten Friedrich, Hermann L Müller","doi":"10.1007/s10198-025-01786-3","DOIUrl":"10.1007/s10198-025-01786-3","url":null,"abstract":"<p><strong>Background: </strong>Rapid and abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and/or treatment-related damage to the hypothalamus, is called acquired hypothalamic obesity (aHO), and is often linked to craniopharyngioma and/or sellar/suprasellar tumors. Here, we examine the healthcare resource use (HCRU) and costs of aHO following treatment of these tumors.</p><p><strong>Methods: </strong>We used a retrospective matched cohort design with German statutory health insurance data on 5.42 million people from 2010 to 2021. We applied a novel three-step approach using diagnostic and prescription data to identify patients with treatment- or tumor-related (TTR)-aHO. We measured HCRU and costs across hospitalizations, outpatient visits, visits per specialist group, and outpatient prescription medications.</p><p><strong>Results: </strong>Compared to non-HO obesity, TTR-aHO is associated with increased hospitalizations, increased outpatient physician visits, and increased prescription use in the two years after incident tumor surgery/radiotherapy. Excess costs of TTR-aHO are €19,900 per patient in the first year and €10,700 in the second, driven by inpatient costs. Cost-intensive hormone replacement therapies like somatropin lead to a sharp increase in prescription costs in the second year.</p><p><strong>Conclusions: </strong>This study provides the first real-world analysis of TTR-aHO economics, emphasizing the importance of HCRU and costs for decision-making. Previously, economic evaluations have been missing due to the lack of a standard method to identify patients with aHO in retrospective studies. Using a new identification approach, the study reveals that TTR-aHO poses a significant burden in extensive treatment requirements for patients and high related costs for the healthcare system.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1557-1567"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Is episodic future thinking effective in mitigating the influence of time preference in time trade-off? 更正:情景未来思维是否能有效缓解时间权衡中时间偏好的影响?
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-10-29 DOI: 10.1007/s10198-025-01862-8
Zhongyu Lang, Liying Zhang, Stefan A Lipman, Bradley Sugden, Kim Rand, Arthur E Attema
{"title":"Correction: Is episodic future thinking effective in mitigating the influence of time preference in time trade-off?","authors":"Zhongyu Lang, Liying Zhang, Stefan A Lipman, Bradley Sugden, Kim Rand, Arthur E Attema","doi":"10.1007/s10198-025-01862-8","DOIUrl":"10.1007/s10198-025-01862-8","url":null,"abstract":"","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1707"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial. 1周vs 3 - 5周石膏固定治疗桡骨远端未复位骨折,成本-效果分析嵌入一项阶梯楔形聚类随机对照试验。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-06-02 DOI: 10.1007/s10198-025-01795-2
Marcel A N de Bruijn, Emily Z Boersma, Lysanne van Silfhout, Tjarda N Tromp, Eddy M M Adang, Erik van de Krol, Michael J R Edwards, Vincent M A Stirler, Erik Hermans

Objective: Distal radius fractures are commonly seen at the Emergency Department. In the Netherlands, non- or minimally displaced fractures are immobilized for 3-5 weeks. However, evidence suggests shorter immobilization yields similar or better functional outcome. There is a lack of cost-effectiveness studies investigating shorter duration of cast immobilization. This study investigates the cost-effectiveness of one week of plaster cast immobilization versus three to five weeks.

Methods: Cost-effectiveness data was collected as part of the Cast-OFF 2 study which started the 1st of January 2022. A randomized stepped wedge cluster design was used with 11 hospitals, and 10 clusters, including patients with an isolated non- or minimally displaced distal radius fracture without fracture reduction. Costs on medical consumption, and productivity were scored with the local Electronical Patient Record, and questionnaires at week one, six, month six, and twelve. Cost-effectiveness was reported per Quality-Adjusted Life Year (QALY).

Results: A total of 402 patients were included (control n = 197 vs intervention n = 205). No differences in QALY were observed (+ 0.02, CI [-0.02, 0.06]). Cost savings for the intervention group ranged from €31.94 to €322.41 depending on different scenarios. The future perspective scenario with reduction of one outpatient clinic visit showed a significant cost saving of €254.27 (CI [-467.33, -41.21]). No significant differences were observed in baseline characteristics.

Conclusion: One week of plaster cast immobilization for non- or minimally displaced distal radius fractures results in comparable or better cost savings compared to usual care. Adopting one week of cast immobilization as the new standard-of-care could reduce healthcare costs.

Trial registration: Netherlands Trial Register NL9278. CMO: 2-21-7308.

目的:桡骨远端骨折常见于急诊科。在荷兰,非或最小移位骨折固定3-5周。然而,有证据表明,较短的固定时间可以产生类似或更好的功能结果。目前还缺乏成本效益研究来研究较短的固定时间。本研究调查了一周石膏固定与三至五周固定的成本效益。方法:收集成本效益数据,作为2022年1月1日开始的castoff 2研究的一部分。采用随机阶梯楔形聚类设计对11家医院和10个聚类进行了研究,其中包括孤立性桡骨远端骨折无骨折复位的患者。通过当地的电子病历和第一周、第6个月、第6个月和第12个月的问卷调查,对医疗消费和生产力的成本进行了评分。按质量调整生命年(QALY)报告成本效益。结果:共纳入402例患者(对照组197例,干预组205例)。两组QALY无差异(+ 0.02,CI[-0.02, 0.06])。根据不同的情况,干预组节省的费用从31.94欧元到322.41欧元不等。从未来的角度来看,减少一次门诊就诊显示节省了254.27欧元的显著成本(CI[-467.33, -41.21])。基线特征无显著差异。结论:与常规治疗相比,一周石膏固定治疗非或轻度移位桡骨远端骨折可节省相当或更好的费用。采用一周石膏固定作为新的护理标准可以降低医疗成本。试验注册:荷兰试验注册NL9278。CMO: 2-21-7308。
{"title":"One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial.","authors":"Marcel A N de Bruijn, Emily Z Boersma, Lysanne van Silfhout, Tjarda N Tromp, Eddy M M Adang, Erik van de Krol, Michael J R Edwards, Vincent M A Stirler, Erik Hermans","doi":"10.1007/s10198-025-01795-2","DOIUrl":"10.1007/s10198-025-01795-2","url":null,"abstract":"<p><strong>Objective: </strong>Distal radius fractures are commonly seen at the Emergency Department. In the Netherlands, non- or minimally displaced fractures are immobilized for 3-5 weeks. However, evidence suggests shorter immobilization yields similar or better functional outcome. There is a lack of cost-effectiveness studies investigating shorter duration of cast immobilization. This study investigates the cost-effectiveness of one week of plaster cast immobilization versus three to five weeks.</p><p><strong>Methods: </strong>Cost-effectiveness data was collected as part of the Cast-OFF 2 study which started the 1st of January 2022. A randomized stepped wedge cluster design was used with 11 hospitals, and 10 clusters, including patients with an isolated non- or minimally displaced distal radius fracture without fracture reduction. Costs on medical consumption, and productivity were scored with the local Electronical Patient Record, and questionnaires at week one, six, month six, and twelve. Cost-effectiveness was reported per Quality-Adjusted Life Year (QALY).</p><p><strong>Results: </strong>A total of 402 patients were included (control n = 197 vs intervention n = 205). No differences in QALY were observed (+ 0.02, CI [-0.02, 0.06]). Cost savings for the intervention group ranged from €31.94 to €322.41 depending on different scenarios. The future perspective scenario with reduction of one outpatient clinic visit showed a significant cost saving of €254.27 (CI [-467.33, -41.21]). No significant differences were observed in baseline characteristics.</p><p><strong>Conclusion: </strong>One week of plaster cast immobilization for non- or minimally displaced distal radius fractures results in comparable or better cost savings compared to usual care. Adopting one week of cast immobilization as the new standard-of-care could reduce healthcare costs.</p><p><strong>Trial registration: </strong>Netherlands Trial Register NL9278. CMO: 2-21-7308.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1645-1654"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncovering the health divide: examining the influence of poverty risk and income inequality on health outcomes in over 300 Finnish municipalities. 揭示健康鸿沟:在芬兰300多个城市研究贫困风险和收入不平等对健康结果的影响。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-05-25 DOI: 10.1007/s10198-025-01780-9
Saqib Amin

The relationship between poverty, income inequality, and health outcomes has been extensively explored in the literature, primarily focusing on cross-country comparisons. However, findings from within-country analyses have yielded inconsistent results. This study investigates the association between poverty risk, income inequality, and health outcomes using Finnish municipality-level data from 1990 to 2023. Fixed-effect models are used to reveal a concerning interplay between these factors by utilizing measures of poverty risk, income inequality, and their synergistic effect, alongside a comprehensive set of health outcome indicators. The findings reveal a significant strong association between both poverty risk and income inequality with various health indicators. Moreover, the analysis also demonstrates a strong combined influence of poverty and inequality, indicating that their combined effect on negative health outcomes is more pronounced. These findings suggest that policies promoting social mobility and reducing income inequality may lead to a healthier Finnish population, particularly low-income residents, with a lower burden of chronic diseases and mortality.

文献对贫困、收入不平等和健康结果之间的关系进行了广泛的探讨,主要集中在跨国比较上。然而,国内分析的结果产生了不一致的结果。本研究利用1990年至2023年芬兰市级数据调查了贫困风险、收入不平等和健康结果之间的关系。使用固定效应模型,利用贫困风险、收入不平等及其协同效应的措施,以及一套全面的健康结果指标,揭示这些因素之间令人担忧的相互作用。调查结果显示,贫困风险和收入不平等与各种健康指标之间存在显著的密切联系。此外,分析还显示了贫穷和不平等的强大综合影响,表明它们对负面健康结果的综合影响更为明显。这些发现表明,促进社会流动和减少收入不平等的政策可能会使芬兰人口,特别是低收入居民更健康,慢性病负担和死亡率也更低。
{"title":"Uncovering the health divide: examining the influence of poverty risk and income inequality on health outcomes in over 300 Finnish municipalities.","authors":"Saqib Amin","doi":"10.1007/s10198-025-01780-9","DOIUrl":"10.1007/s10198-025-01780-9","url":null,"abstract":"<p><p>The relationship between poverty, income inequality, and health outcomes has been extensively explored in the literature, primarily focusing on cross-country comparisons. However, findings from within-country analyses have yielded inconsistent results. This study investigates the association between poverty risk, income inequality, and health outcomes using Finnish municipality-level data from 1990 to 2023. Fixed-effect models are used to reveal a concerning interplay between these factors by utilizing measures of poverty risk, income inequality, and their synergistic effect, alongside a comprehensive set of health outcome indicators. The findings reveal a significant strong association between both poverty risk and income inequality with various health indicators. Moreover, the analysis also demonstrates a strong combined influence of poverty and inequality, indicating that their combined effect on negative health outcomes is more pronounced. These findings suggest that policies promoting social mobility and reducing income inequality may lead to a healthier Finnish population, particularly low-income residents, with a lower burden of chronic diseases and mortality.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1581-1595"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach. 使用优先设置方法对澳大利亚儿童龋齿预防干预进行经济评估。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-04-30 DOI: 10.1007/s10198-025-01787-2
Tan Minh Nguyen, Long Khanh-Dao Le, Hanny Calache, Cathrine Mihalopoulos

This study aims to economically evaluate three preventive interventions for dental caries among Australian children from low household income. The interventions included: (1) anticipatory guidance provided by oral health therapists via 1a) home visits or 1b) telehealth consultations; (2) school-based dental screening and fluoride varnish program delivered by 2a) dental practitioners or 2b) non-dental health professionals (no screening); and (3) school-based fissure sealant program. The base-case scenario included intervention and dental treatment costs, with six-year (1a and 1b) and two-year (2a, 2b and 3) time horizons. Sensitivity analysis included other healthcare costs (e.g. pulp therapy, extractions, etc.). Additionally, extrapolation modelling extended the 12-year time horizon (all interventions). Probability for cost-effectiveness applied AUD$50,000 per disability-adjusted life year (DALY) averted, and AUD$28,033 per quality-adjusted life year (QALY) gained willingness-to-pay thresholds. Under the base-case scenario, none of the interventions were cost-effective. Cost-effectiveness results were sensitive when including other healthcare costs and the 12-year time horizon. Probability for cost-effectiveness (DALYs averted/QALYs gained) with extrapolation modelling in order of ranking were: (1) 91.5%/94.7% for fluoride varnish, (2) 43.9%/48.6% for dental screening and fluoride varnish, (3) 28.7%/29.8% for anticipatory guidance via telehealth, (4) 17.1%/20.0% for fissure sealant, and (5) 2.2%/2.2% for anticipatory guidance via home visits.

本研究旨在经济地评估澳大利亚低收入家庭儿童龋齿的三种预防干预措施。干预措施包括:(1)口腔健康治疗师通过1a)家访或1b)远程医疗咨询提供预期指导;(2)由2a)牙科从业者或2b)非牙科保健专业人员(无筛查)提供的以学校为基础的牙科筛查和氟化物清漆计划;(3)校本裂缝密封方案。基本情景包括干预和牙科治疗费用,时间跨度为6年(1a和1b)和2年(2a、2b和3)。敏感性分析包括其他医疗保健费用(如牙髓治疗、拔牙等)。此外,外推模型延长了12年的时间范围(所有干预措施)。每个残疾调整生命年(DALY)避免的成本效益概率为50,000澳元,每个质量调整生命年(QALY)获得的支付意愿阈值为28,033澳元。在基本情景下,没有一种干预措施具有成本效益。在包括其他医疗保健费用和12年时间范围时,成本效益结果是敏感的。外推模型的成本-效果概率(避免的DALYs /获得的QALYs)排序依次为:(1)氟化清漆的91.5%/94.7%,(2)牙齿筛查和氟化清漆的43.9%/48.6%,(3)远程医疗预期指导的28.7%/29.8%,(4)缝封剂的17.1%/20.0%,(5)家访预期指导的2.2%/2.2%。
{"title":"Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach.","authors":"Tan Minh Nguyen, Long Khanh-Dao Le, Hanny Calache, Cathrine Mihalopoulos","doi":"10.1007/s10198-025-01787-2","DOIUrl":"10.1007/s10198-025-01787-2","url":null,"abstract":"<p><p>This study aims to economically evaluate three preventive interventions for dental caries among Australian children from low household income. The interventions included: (1) anticipatory guidance provided by oral health therapists via 1a) home visits or 1b) telehealth consultations; (2) school-based dental screening and fluoride varnish program delivered by 2a) dental practitioners or 2b) non-dental health professionals (no screening); and (3) school-based fissure sealant program. The base-case scenario included intervention and dental treatment costs, with six-year (1a and 1b) and two-year (2a, 2b and 3) time horizons. Sensitivity analysis included other healthcare costs (e.g. pulp therapy, extractions, etc.). Additionally, extrapolation modelling extended the 12-year time horizon (all interventions). Probability for cost-effectiveness applied AUD$50,000 per disability-adjusted life year (DALY) averted, and AUD$28,033 per quality-adjusted life year (QALY) gained willingness-to-pay thresholds. Under the base-case scenario, none of the interventions were cost-effective. Cost-effectiveness results were sensitive when including other healthcare costs and the 12-year time horizon. Probability for cost-effectiveness (DALYs averted/QALYs gained) with extrapolation modelling in order of ranking were: (1) 91.5%/94.7% for fluoride varnish, (2) 43.9%/48.6% for dental screening and fluoride varnish, (3) 28.7%/29.8% for anticipatory guidance via telehealth, (4) 17.1%/20.0% for fissure sealant, and (5) 2.2%/2.2% for anticipatory guidance via home visits.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1525-1537"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes. 人员短缺与长期护理的提供:德国养老院的实证分析。
IF 3 3区 医学 Q1 ECONOMICS Pub Date : 2025-12-01 Epub Date: 2025-05-09 DOI: 10.1007/s10198-025-01782-7
Dörte Heger, Annika Herr, Maximilian Lückemann, Arndt Reichert, Leonie Tycher

Amidst demographic shifts, advanced economies are facing critical nursing shortages. This study analyzes how long-term care in German nursing homes relate to these shortages using administrative data for the period 2007 to 2017. Our analysis reveals that higher nursing shortages correlate with decreased nurse-to-resident ratios, changes in the qualification mix of nurse personnel, and reduced occupancy rates. These findings suggest that nurse shortages might be a threat to the quality of care and the financial sustainability of nursing homes at the margin of being profitable.

随着人口结构的变化,发达经济体正面临着严重的护理短缺。本研究使用2007年至2017年期间的行政数据分析了德国养老院的长期护理与这些短缺之间的关系。我们的分析表明,较高的护理短缺与护士与住院医师比例下降、护士人员资格组合的变化以及入住率下降有关。这些发现表明,护士短缺可能会威胁到护理质量和养老院在盈利边缘的财务可持续性。
{"title":"Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes.","authors":"Dörte Heger, Annika Herr, Maximilian Lückemann, Arndt Reichert, Leonie Tycher","doi":"10.1007/s10198-025-01782-7","DOIUrl":"10.1007/s10198-025-01782-7","url":null,"abstract":"<p><p>Amidst demographic shifts, advanced economies are facing critical nursing shortages. This study analyzes how long-term care in German nursing homes relate to these shortages using administrative data for the period 2007 to 2017. Our analysis reveals that higher nursing shortages correlate with decreased nurse-to-resident ratios, changes in the qualification mix of nurse personnel, and reduced occupancy rates. These findings suggest that nurse shortages might be a threat to the quality of care and the financial sustainability of nursing homes at the margin of being profitable.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1539-1555"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Health Economics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1